1.06
-0.03(-2.75%)
Currency In USD
Previous Close | 1.09 |
Open | 1.07 |
Day High | 1.09 |
Day Low | 1 |
52-Week High | 4.32 |
52-Week Low | 0.6 |
Volume | 257,203 |
Average Volume | 615,862 |
Market Cap | 5.08M |
PE | -0.17 |
EPS | -6.07 |
Moving Average 50 Days | 0.78 |
Moving Average 200 Days | 1.39 |
Change | -0.03 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of July 31, 2025 at a share price of $1.06. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.29 as of July 31, 2025 at a share price of $1.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
GlobeNewswire Inc.
Jul 24, 2025 12:00 AM GMT
Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune,
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
GlobeNewswire Inc.
Jul 22, 2025 12:45 PM GMT
– Video webcast now available on-demand Carlsbad, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
GlobeNewswire Inc.
Jul 09, 2025 12:45 PM GMT
Figure: 1 Palisade Bio, Inc. Appoints Emil Chuang, MB BS FRACP to its Board of Directors Veteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcera